COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 23 04 2019
revised: 10 10 2019
accepted: 21 10 2019
pubmed: 12 11 2019
medline: 12 3 2021
entrez: 12 11 2019
Statut: ppublish

Résumé

Genome-wide association studies (GWAS) have identified several loci contributing to lung cancer and COPD risk independently; however, inflammation-related pathways likely harbor additional lung cancer risk-associated variants in biologically relevant immune genes that differ dependent on COPD. We selected single nucleotide polymorphisms (SNPs) proximal to 2,069 genes within 48 immune pathways. We modeled the contribution of these variants to lung cancer risk in a discovery sample of 1,932 lung cancer cases and controls stratified by COPD status and validation sample of 953 cases and controls also stratified by COPD. There were 43 validated SNPs in those with COPD and 60 SNPs in those without COPD associated with lung cancer risk. Furthermore, 29 of 43 and 28 of 60 SNPs demonstrated a statistically significant interaction with COPD in the pooled sample. These variants demonstrated tissue-dependent effects on proximal gene expression, enhanced network connectivity and resided together in specific immune pathways. These results reveal that key inflammatory related genes and pathways, not found in prior GWAS, impact lung cancer risk in a COPD-dependent manner. Genetic variation identified in our study supplements prior lung cancer GWAS and serves as a foundation to further interrogate risk relationships in smoking and COPD populations.

Identifiants

pubmed: 31709530
doi: 10.1002/ijc.32780
pmc: PMC7211135
mid: NIHMS1059869
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

747-756

Subventions

Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA141769
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009531
Pays : United States

Informations de copyright

© 2019 UICC.

Références

Chest. 2003 Jan;123(1 Suppl):21S-49S
pubmed: 12527563
Nature. 2008 Apr 3;452(7187):633-7
pubmed: 18385738
J Natl Cancer Inst. 2010 Jul 7;102(13):959-71
pubmed: 20548021
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Nat Genet. 2008 May;40(5):616-22
pubmed: 18385676
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1213-21
pubmed: 22573796
Respiration. 2011;81(5):362-71
pubmed: 21228544
Nature. 2008 Apr 3;452(7187):638-642
pubmed: 18385739
Cancer. 2012 Nov 15;118(22):5630-6
pubmed: 23044494
Hum Mutat. 2009 Jan;30(1):69-78
pubmed: 18683858
Lancet. 2004 Aug 21-27;364(9435):709-21
pubmed: 15325838
Am J Hum Genet. 2009 Nov;85(5):679-91
pubmed: 19836008
Nucleic Acids Res. 2014 Jan;42(Database issue):D472-7
pubmed: 24243840
J Thorac Dis. 2013 Oct;5 Suppl 5:S454-62
pubmed: 24163739
PLoS One. 2012;7(10):e46071
pubmed: 23056235
PLoS One. 2011 Feb 03;6(2):e16476
pubmed: 21304900
Genes (Basel). 2017 Jan 17;8(1):
pubmed: 28106732
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Hum Genet. 2013 May;132(5):579-89
pubmed: 23370545
Nucleic Acids Res. 2008 Dec;36(21):6795-805
pubmed: 18953043
Lung Cancer. 2016 Aug;98:33-42
pubmed: 27393504
J Natl Cancer Inst. 2015 Aug 29;107(11):
pubmed: 26319099
Nat Rev Cancer. 2013 Apr;13(4):233-45
pubmed: 23467302
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Apoptosis. 2009 Apr;14(4):348-63
pubmed: 19212815
Cancer Res. 2007 Jul 1;67(13):6520-7
pubmed: 17596594
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1341-7
pubmed: 27383774
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Proc Am Thorac Soc. 2006 Aug;3(6):535-7
pubmed: 16921139
Clin Lung Cancer. 2003 Jul;5(1):46-62
pubmed: 14596704
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
PLoS One. 2009 Oct 08;4(10):e7380
pubmed: 19812684

Auteurs

Donovan Watza (D)

Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Karmanos Cancer Institute, Detroit, MI.

Christine M Lusk (CM)

Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Karmanos Cancer Institute, Detroit, MI.

Gregory Dyson (G)

Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Karmanos Cancer Institute, Detroit, MI.

Kristen S Purrington (KS)

Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Karmanos Cancer Institute, Detroit, MI.

Angela S Wenzlaff (AS)

Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Karmanos Cancer Institute, Detroit, MI.

Christine Neslund-Dudas (C)

Department of Public Health Sciences, Henry Ford Health System and Henry Ford Cancer Institute, Detroit, MI.

Ayman O Soubani (AO)

Karmanos Cancer Institute, Detroit, MI.
Department of Internal Medicine, School of Medicine, Wayne State University, Detroit, MI.

Shirish M Gadgeel (SM)

Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.

Ann G Schwartz (AG)

Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Karmanos Cancer Institute, Detroit, MI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH